Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter De Cruz

Showing results (21-30 of 128) with videos related to

Pageof 13
Sort By:
Inflammatory Bowel Diseases|January 19, 2022
Combination Tofacitinib and Calcineurin Inhibitor in the Management of Treatment-Refractory Ulcerative Colitis May Be Effective, But Is It Necessary?Adam R Peterson, Patrick Hilley, Peter De Cruz
Alimentary Pharmacology & Therapeutics|July 14, 2020
Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval?Ashish Srinivasan, Peter De Cruz, Daniel R van Langenberg
Scandinavian Journal of Gastroenterology|June 10, 2017
eHealth for inflammatory bowel disease self-management - the patient perspectiveDanny Con, Belinda Jackson, Kathleen Gray, et al.
BMJ Case Reports|October 1, 2018
Pneumatosis cystoides intestinalis (PCI) in a patient with undiagnosed systemic sclerosisGurpreet Singh, Christopher Johnson, Rosie Gill, et al.
Gut|July 19, 2020
Anti-TNF-associated immunogenicity: use a retroactive drug but a proactive approachAshish Srinivasan, Peter De Cruz, Daniel R van Langenberg
Alimentary Pharmacology & Therapeutics|July 14, 2020
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detailAshish Srinivasan, Peter De Cruz, Daniel R van Langenberg
Journal of Crohn'S & Colitis|September 19, 2025
Implementation of Values based healthcare in inflammatory bowel disease-a review articlePatrick Hilley, Simone Chin, Darren Wong, et al.
Therapeutic Advances in Gastroenterology|February 7, 2022
Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn's diseaseAshish Srinivasan, Robert Gilmore, Daniel van Langenberg, et al.
Scandinavian Journal of Gastroenterology|January 28, 2017
Clinicians' adherence to international guidelines in the clinical care of adults with inflammatory bowel diseaseBelinda D Jackson, Danny Con, Danny Liew, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 11, 2021
Impact of Inflammatory Bowel Disease and Azathioprine on Long-Term Outcomes After Liver Transplantation for Primary Sclerosing CholangitisMatthew Peverelle, Peter De Cruz, Sarang Paleri, et al.
Pageof 13

Showing results (21-30 of 128) with videos related to

Sort By:
Pageof 13
Inflammatory Bowel Diseases|January 19, 2022
Combination Tofacitinib and Calcineurin Inhibitor in the Management of Treatment-Refractory Ulcerative Colitis May Be Effective, But Is It Necessary?Adam R Peterson, Patrick Hilley, Peter De Cruz
Alimentary Pharmacology & Therapeutics|July 14, 2020
Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval?Ashish Srinivasan, Peter De Cruz, Daniel R van Langenberg
Scandinavian Journal of Gastroenterology|June 10, 2017
eHealth for inflammatory bowel disease self-management - the patient perspectiveDanny Con, Belinda Jackson, Kathleen Gray, et al.
BMJ Case Reports|October 1, 2018
Pneumatosis cystoides intestinalis (PCI) in a patient with undiagnosed systemic sclerosisGurpreet Singh, Christopher Johnson, Rosie Gill, et al.
Gut|July 19, 2020
Anti-TNF-associated immunogenicity: use a retroactive drug but a proactive approachAshish Srinivasan, Peter De Cruz, Daniel R van Langenberg
Alimentary Pharmacology & Therapeutics|July 14, 2020
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detailAshish Srinivasan, Peter De Cruz, Daniel R van Langenberg
Journal of Crohn'S & Colitis|September 19, 2025
Implementation of Values based healthcare in inflammatory bowel disease-a review articlePatrick Hilley, Simone Chin, Darren Wong, et al.
Therapeutic Advances in Gastroenterology|February 7, 2022
Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn's diseaseAshish Srinivasan, Robert Gilmore, Daniel van Langenberg, et al.
Scandinavian Journal of Gastroenterology|January 28, 2017
Clinicians' adherence to international guidelines in the clinical care of adults with inflammatory bowel diseaseBelinda D Jackson, Danny Con, Danny Liew, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 11, 2021
Impact of Inflammatory Bowel Disease and Azathioprine on Long-Term Outcomes After Liver Transplantation for Primary Sclerosing CholangitisMatthew Peverelle, Peter De Cruz, Sarang Paleri, et al.
Pageof 13